ClearPoint Neuro/$CLPT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ClearPoint Neuro
ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.
Ticker
$CLPT
Sector
Primary listing
Employees
172
Headquarters
Website
ClearPoint Neuro Metrics
BasicAdvanced
$448m
-
-$1.01
1.29
-
Price and volume
Market cap
$448m
Beta
1.29
52-week high
$30.10
52-week low
$8.27
Average daily volume
669k
Financial strength
Current ratio
5.789
Quick ratio
4.75
Long term debt to equity
336.256
Total debt to equity
337.498
Interest coverage (TTM)
-6.55%
Profitability
EBITDA (TTM)
-23.606
Gross margin (TTM)
62.33%
Net profit margin (TTM)
-71.57%
Operating margin (TTM)
-60.76%
Effective tax rate (TTM)
-0.16%
Revenue per employee (TTM)
$240,000
Management effectiveness
Return on assets (TTM)
-24.98%
Return on equity (TTM)
-149.72%
Valuation
Price to revenue (TTM)
10.584
Price to book
23.78
Price to tangible book (TTM)
-218.54
Price to free cash flow (TTM)
-16.097
Free cash flow yield (TTM)
-6.21%
Free cash flow per share (TTM)
-0.928
Growth
Revenue change (TTM)
25.99%
Earnings per share change (TTM)
34.06%
3-year revenue growth (CAGR)
24.68%
10-year revenue growth (CAGR)
23.36%
3-year earnings per share growth (CAGR)
10.88%
10-year earnings per share growth (CAGR)
-11.14%
What the Analysts think about ClearPoint Neuro
Analyst ratings (Buy, Hold, Sell) for ClearPoint Neuro stock.
ClearPoint Neuro Financial Performance
Revenues and expenses
ClearPoint Neuro Earnings Performance
Company profitability
ClearPoint Neuro News
AllArticlesVideos
ClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel
Accesswire·3 days ago
ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026
Accesswire·2 weeks ago
ClearPoint Neuro Enters into 10-year Focused Ultrasound Development Partnership with Sungkyunkwan University, South Korea, Further Expanding Our Drug Delivery Ecosystem and Global Footprint
Accesswire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.